AI Summary
Platinum-based drugs in cancer chemotherapy have limitations due to side effects and drug resistance. Targeting specific organelles in cancer cells can overcome these challenges, as organelle-targeted platinum complexes have shown increased anticancer activity, can overcome drug resistance, and have lower toxicity. This review discusses various organelle-targeting strategies and their mechanisms in improving anticancer performance. It aims to assist researchers in developing platinum complexes.
Platinum-based drugs have revolutionized cancer chemotherapy; however, their therapeutic efficacy has been limited by severe side effects and drug resistance. Recently, approaches that target specific organelles in cancer cells have emerged as attractive alternatives to overcome these challenges. Many studies have validated these strategies and highlighted that organelle-targeted platinum complexes demonstrate increased anticancer activity, the ability to overcome drug resistance, novel molecular mechanisms, or even lower toxicity. This review provides a brief summary of various organelle-targeting strategies that promote the accumulation of platinum complexes in certain intracellular areas, such as the nucleus, mitochondria, endoplasmic reticulum (ER), and lysosomes. Moreover, the mechanisms through which these strategies improve anticancer performance, overcome drug resistance, and alter the action mode of conventional platinum drugs are discussed. By providing an extensive account of platinum complexes targeting different organelles, this review aims to assist researchers in understanding the design principles, identifying potential targets, and fostering innovative ideas for the development of platinum complexes.
This article is Open Access
Please wait while we load your content… Something went wrong. Try again?